Onkofar Sağlık Ürünleri A.Ş. Revenue and Competitors
Estimated Revenue & Valuation
- Onkofar Sağlık Ürünleri A.Ş.'s estimated annual revenue is currently $8M per year.
- Onkofar Sağlık Ürünleri A.Ş.'s estimated revenue per employee is $251,000
Employee Data
- Onkofar Sağlık Ürünleri A.Ş. has 32 Employees.
- Onkofar Sağlık Ürünleri A.Ş. grew their employee count by 3% last year.
Onkofar Sağlık Ürünleri A.Ş.'s People
Name | Title | Email/Phone |
---|
Onkofar Sağlık Ürünleri A.Ş. Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5M | 40 | -18% | $10M | N/A |
#2 | $24.8M | 99 | 29% | N/A | N/A |
#3 | $84.1M | 0 | N/A | $1.2M | N/A |
#4 | $35.6M | 142 | 30% | N/A | N/A |
#5 | $57.5M | 229 | 6% | N/A | N/A |
#6 | $52.7M | 168 | 25% | $129.6M | N/A |
#7 | $21.1M | 84 | -3% | N/A | N/A |
#8 | $61.2M | 244 | -13% | N/A | N/A |
#9 | $60.6M | 193 | 20% | $115.5M | N/A |
#10 | $56.2M | 179 | -3% | $122.9M | N/A |
What Is Onkofar Sağlık Ürünleri A.Ş.?
Onkofar was established in 2011 with subsidiaries of both experienced company in the healthcare sector: Med-Kim and Endotek in Izmir to provide innovative and high-tech solutions in the field of oncology for the safety of patients and health professionals. We as Onkofar, with a vision to lead the development of chemotherapy drug preparation and administration services in the field of oncology; providing integrated solutions; from intravenous drug preparation accordance with national and international legislation and standarts, to the stage of administration process of the cytotoxic drugs to the patient.
keywords:N/AN/A
Total Funding
32
Number of Employees
$8M
Revenue (est)
3%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $5.2M | 32 | -18% | N/A |
#2 | $3.7M | 32 | N/A | N/A |
#3 | $3.7M | 32 | N/A | N/A |
#4 | $6.4M | 32 | N/A | N/A |
#5 | $3.7M | 32 | N/A | N/A |